| Name | Title | Contact Details |
|---|---|---|
Emily Pullen |
VP of Human Resources | Profile |
Debra Vasques Bruneau |
Vice President Human Resources | Profile |
C.W. Juhl Consulting is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For nearly 30 years, Press Ganey`s mission has been to support health care providers in understanding and improving the entire patient experience. As a strategic business partner to more than 10,000 health care organizations across the country and across the continuum of care, we are the leader in helping create continuous, sustainable improvement. Headquartered in South Bend, Indiana, Press Ganey serves clients nationwide with locally based teams of associates to ensure strong client connections and relationships. As a result, Press Ganey is acutely aware of the challenges and opportunities unique to specific providers and their communities. Our associates are professionals, deeply rooted in health care and strongly committed to our clients` success. Whether it`s in the hospital, medical practice, ambulatory or home care setting, we partner with clients to create and sustain a high-performance environment to ultimately improve the patient experience. Our comprehensive suite of health care solutions helps clients meet their goals of improved quality, better care and lower costs. Press Ganey provides both ongoing advisory services and consulting in all phases of performance improvement. Our patient experience advisors are uniquely trained and skilled to identify areas of opportunity and help clients implement targeted improvement plans. Our consultants, whose health care experience is a true differentiator, work in partnership with organizations to identify and implement best practices across their operations. Simply put, we are vested in our clients` success, and dedicated to helping understand and improve every dimension of the patient experience.
Schwabe North America is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.